An Overview of the Research Advancements in Bispecific Antibodies
According to the Pharmacodia Database, currently, there have been 13 drugs approved worldwide in this field. However, Removab was withdrawn from the market in 2017 due to its strong immunogenicity and commercial reasons.
August 30, 2023
by Dopine/PharmaSources
Innovent Biologics enters drug development deal with Roche
Chinese biopharmaceutical firm Innovent Biologics has entered a strategic research and development partnership with Roche for various cell therapies and bispecific antibodies.
June 10, 2020
by pharmaceutical-technology
WuXi Biologics and Almirall Sign Strategic Collaboration Agreement for Multiple Bispecific Antibodies Targeting Dermatology Diseases
WuXi Biologics announced the signing of a strategic collaboration agreement enabling Almirall to leverage the proprietary WuXiBody™ platform to develop bispecific antibodies for dermatological diseases.
January 9, 2020
by En-CPhI.CN
GSK expands bispecific antibodies deal with Zymeworks
GlaxoSmithKline (GSK) has expanded its licensing and collaboration agreement with Canadian biotechnology firm Zymeworks.
May 22, 2019
by pharmaceutical-technology
Abpro, NJCTTQ to develop multiple novel bispecific antibodies
NJCTTQ to have exclusive commercial rights to approved molecules in China; Abpro to retain commercial rights for all other major regions.
March 4, 2019
by biospectrumasia
EpimAb announces IND filing for EMB01
IND filing marks further progress towards the first clinical trial with the Company’s Novel Bispecific Antibody Format.
September 18, 2018
by biospectrumasia
F-Star Expands Relationship with Merck to Develop Bispecific Antibodies in Immuno-Oncology
F-star announced a new partnership with Merck for the development and commercialization of five bispecific immuno-oncology antibodies (mAb2).
June 7, 2017
by americanpharmaceuticalreview